Flexible Stopping Boundaries When Changing Primary Endpoints After Unblinded Interim Analyses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Flexible Stopping Boundaries When Changing Primary Endpoints After Unblinded Interim Analyses

Published:2014-05-14 Issue:4 Volume:24 Page:817-833
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Chen Liddy M.¹,Ibrahim Joseph G.²,Chu Haitao³

Affiliation:

1. Global Research Operation, Biostatistics, PAREXEL International, Durham, North Carolina, USA

2. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA

3. Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2014.901341

Reference35 articles.

1. Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials

2. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)

3. Sample size and power determination in joint modeling of longitudinal and survival data

4. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE PROGNOSTIC ROLE OF PRE-TREATMENT PLATELET-TO-LYMPHOCYTE RATIO IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS;Journal of Evidence-Based Dental Practice;2023-12

2. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC;Nature Cancer;2023-06-15

3. Adaptive Endpoints Selection with Application in Rare Disease;Statistics in Biopharmaceutical Research;2023-04-07

4. A protocol pre-specified interim overall survival analysis of the randomised phase III GEMSTONE-302 trial: sugemalimab or placebo plus platinum-based chemotherapy for first-line metastatic non-small-cell lung cancer;2022-10-07

5. Pre‐treatment neutrophil‐to‐lymphocyte ratio is an independent prognostic factor in head and neck squamous cell carcinoma: Meta‐analysis and trial sequential analysis;Journal of Oral Pathology & Medicine;2021-12-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3